Floatz logo

RADIUM RA-223

Prostatic Neoplasms

BayerOtherPhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
73/ 100

Competitive context

74 Active assets in the Prostatic Neoplasms cohort.

Asset / SponsorPhaseRating
Docetaxel
Merck Sharp & Dohme LLC
Phase 4BBB
Degarelix
Novartis Pharmaceuticals
Phase 4BBB
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 3BBB
LEUPROLIDE
Dana-Farber Cancer Institute
Phase 4BB
Abiraterone Acetate
Qilu Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

RADIUM RA-223 is also rated in:

castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
metastatic carcinoma in the boneDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →